Low phosphate after Ferinject: what patients and parents should know

Ferinject (ferric carboxymaltose) is a widely used intravenous iron treatment that can be very effective in restoring iron levels quickly. It is generally well tolerated and helps many patients who cannot take or absorb oral iron.

However, one known and important potential side effect is low phosphate levels (hypophosphataemia). While uncommon in routine practice, it is significant enough that awareness and selective monitoring are sometimes recommended.

What is phosphate, and why does it matter?

Phosphate is a mineral that plays a key role in several essential body functions. It is involved in:

• Muscle function – helping muscles contract and work effectively
• Energy production – supporting how the body generates and uses energy
• Bone health – contributing to bone strength and mineralisation

Because of these roles, significant drops in phosphate levels can affect energy, strength, and bone health.

What symptoms can low phosphate cause?

Many cases are mild or temporary and may not cause noticeable symptoms. However, when phosphate levels become more significantly reduced, symptoms may include:

• Increasing or unexplained fatigue
• Muscle aches or generalised pain (myalgias)
• Bone pain or discomfort
• Muscle weakness or reduced physical strength

In more severe or prolonged cases, symptoms can become more pronounced. If symptoms are worsening, persistent, or concerning, medical review is important.

Why is this associated with Ferinject?

Ferinject is effective because it delivers iron in a form that can be rapidly absorbed and used by the body. However, in some individuals, it can trigger a drop in phosphate levels.

Regulatory safety updates and clinical guidance have reported rare but important cases where persistent hypophosphataemia has led to complications such as osteomalacia (softening of the bones) and fractures.

It is important to emphasise that these outcomes are uncommon, but they highlight why awareness and appropriate monitoring in selected cases are important.

Who is more likely to need phosphate monitoring?

Routine monitoring is not required for everyone. However, it may be more relevant in individuals who:

• Require multiple high-dose Ferinject infusions
• Are you receiving repeated or long-term intravenous iron treatment
• Have underlying conditions that affect absorption or metabolism, such as:
  – Coeliac disease
  – Inflammatory bowel disease (IBD)
• Have other risk factors for altered mineral balance

In these situations, clinicians may choose to check phosphate levels before or after treatment.

Our approach at The Health Suite (14–18 pathway)

Within our specialist-led young people’s pathway, safety monitoring is built into clinical decision-making.

We:

• Assess individual risk factors for low phosphate during consultation
• Consider baseline phosphate testing where appropriate
• Arrange follow-up blood tests when clinically indicated
• Provide clear guidance on what symptoms to watch for after treatment
• Ensure families understand when to seek medical advice

This structured approach helps ensure treatment is both effective and safe, particularly in adolescents, where growth and bone health are important considerations.

Why this matters for parents and guardians

For most teenagers, IV iron treatment is straightforward, effective, and well-tolerated. Significant phosphate-related side effects are uncommon, but awareness allows them to be identified early if they do occur.

The purpose of monitoring is not to alarm, but to ensure that treatment remains safe and that any rare complications are detected and managed promptly.

A balanced perspective

Ferinject remains a valuable treatment option for iron deficiency, particularly when oral iron is not suitable or effective. Like all medical treatments, it has potential risks, but these are carefully considered against the benefits.

With appropriate assessment, dosing, and follow-up, IV iron therapy can be delivered safely and effectively — even in younger patients.